Zentalis' Azenosertib Plus Paclitaxel Shows 39% ORR, 7.3-Month PFS in Platinum-Resistant Ovarian Cancer Phase 1b Trial
ZNTL has more than doubled off its 52-week low of $1.13.
Summary
Zentalis Pharmaceuticals reported detailed positive Phase 1b MUIR trial data for azenosertib combined with paclitaxel in platinum-resistant ovarian cancer. The trial showed an Overall Response Rate (ORR) of 39.1% and a median Progression-Free Survival (PFS) of 7.3 months, significantly outperforming historical paclitaxel monotherapy. This follows an 8-K filed earlier today announcing encouraging results and an April news item about the abstract. The encouraging clinical activity and manageable safety profile suggest strong potential for the drug in this indication. The data will be presented at ASCO 2026 on June 1st.
At the time of this announcement, ZNTL was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $294.7M. The 52-week trading range was $1.13 to $6.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.